Peter Brünker

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Ekkehard Mössner, Peter Brünker, Samuel Moser et al. · Blood · 2010 · 957 citations · Full text

Life Sciences, Immunology, Oncology +17

Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose

Claudia Ferrara, Sandra Grau, Christiane Jäger et al. · Proceedings of the National Academy of Sciences · 2011 · 761 citations

Pharmacy, Biochemistry, Immunology +17

The Carbohydrate at FcγRIIIa Asn-162

Claudia Ferrara, Fiona Stuart, Peter Sondermann et al. · Journal of Biological Chemistry · 2005 · 349 citations · Full text

Life Sciences, Biochemistry, Immunology +17

Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐<i>N</i>‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II

Claudia Ferrara, Peter Brünker, Tobias Suter et al. · Biotechnology and Bioengineering · 2006 · 303 citations

Life Sciences, Biochemistry, Molecular Biology +17

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

Christian Klein, Inja Waldhauer, Valeria Nicolini et al. · OncoImmunology · 2017 · 283 citations · Full text

Life Sciences, Immunology, Oncology +17